Anlon Healthcare Limited is coming up with its Initial Public Offering (IPO) to raise capital for working capital, capital expenditure requirements, and to reduce debt. The IPO comprises entirely a fresh issue of 1.33 crore equity shares. The total offer size aggregates up to Rs. 121.03 crore.
The IPO opens on August 26, 2025, and closes on August 29, 2025. The shares will be listed on NSE and BSE on Wednesday, September 3, 2025. Here’s everything you need to know.
GMP of Anlon Healthcare IPO
As of August 21, 2025, the GMP for Anlon Healthcare IPO has not yet started. Investors should wait for updates as GMP information will be provided once available..
Overview of Anlon Healthcare Limited
Anlon Healthcare Limited, incorporated in 2013, is a chemical manufacturing company focused on producing pharma intermediates and active pharmaceutical ingredients (APIs). These products are widely used in medicines, nutraceuticals, personal care, and veterinary health products.
The company manufactures high-purity products following global standards like IP, BP, EP, JP, and USP. It also provides custom chemical manufacturing, meeting specific customer needs by exceeding purity standards. Anlon Healthcare has received DMF approvals from global authorities, including ANVISA, NMPA, and PMDA. It has also filed 21 DMFs and is preparing to file more for key products.
Currently, the company has a portfolio of 65 commercialized products, 28 in the pilot stage, and 49 under laboratory testing. Supported by four labs and a skilled 34-member science team, Anlon ensures consistent quality. As of January 2025, the company employed 105 staff and 8 contract workers.
Promoters of Anlon Healthcare Limited
The promoters of Anlon Healthcare Limited are Punitkumar R. Rasadia, Meet Atulkumar Vachhani, and Mamata Punitkumar Rasadia. They bring years of expertise in medical equipment distribution and business operations.
Lead Managers of Anlon Healthcare Limited IPO
Interactive Financial Services Limited is the sole Book Running Lead Manager of the IPO. KFin Technologies Limited is acting as the registrar for the issue.
Objectives of the IPO Offer
Anlon Healthcare Limited plans to utilize the IPO proceeds for four primary purposes. The company will allocate Rs. 30.72 crore towards funding capital expenditure requirements for its proposed expansion projects.
Additionally, Rs. 5 crore will be used to repay or prepay certain outstanding secured borrowings availed through term loans. A further Rs. 43.15 crore will be directed towards meeting the company’s working capital requirements to support operations. The remaining funds will be utilized for general corporate purposes, strengthening the company’s overall financial flexibility and strategic growth initiatives.
Financial Analysis of Anlon Healthcare Limited
Anlon Healthcare Limited’s revenue has increased from Rs. 66.58 crore in FY24 to Rs. 120.29 crore in FY25, which represents a growth of 80.67 percent. The net profit has increased by 65.70 percent, from Rs. 9.66 crore in FY24 to Rs. 20.52 crore in FY25.
The basic earnings per share decreased by 4.49 percent and stood at Rs. 6.38 in FY25 as against Rs. 6.68 recorded in FY24. In terms of return ratios, the company’s ROCE and ROE stand at 21.93 percent and 40.45 percent, respectively. Patel Retail Limited’s debt-to-equity ratio is 0.73x.
Anlon Healthcare Limited vs Peers
Anlon Healthcare Limited reported an EPS of Rs. 6.38 and a RoNW of 25.51 percent. In comparison, Kronox Lab Sciences Limited’s EPS of Rs. 6.91, and its RoNW of 28.26 percent. AMI Organics Limited reported Rs. 19.81 EPS, and a RoNW of 12.15 percent, and Supriya Lifeciences Limited reported Rs. 23.35 EPS, and a RoNW of 18.86 percent.
Anlon Healthcare Limited’s net asset value per share is Rs. 20.18, compared to Rs. 24.28 for Kronox Lab Sciences Limited, Rs. 161.24 for AMI Organics Limited, and Rs. 123.85 for Supriya Lifeciences Limited.
Strengths of Anlon Healthcare Limited
- Strong promoter experience ensures robust leadership and long-term company vision.
- Wide product portfolio caters to diverse healthcare and pharmaceutical industry demands.
- Commitment to quality standards builds trust with clients and regulators.
- Strategic location in Gujarat provides logistical and operational advantages.
- Focus on compliance strengthens brand reputation and business sustainability.
Weaknesses of Anlon Healthcare Limited
- High dependency on market demand fluctuations increases business risk exposure.
- Relatively small scale limits bargaining power with larger competitors.
- Significant working capital requirements strain short-term liquidity resources.
- Business concentration in healthcare exposes the company to sector-specific risks.
- First-time IPO listing poses uncertainty in post-listing share performance.
Conclusion
Anlon Healthcare Limited’s IPO offers investors exposure to India’s growing healthcare and pharmaceutical sector. Its experienced promoters, strategic operations, and financial growth highlight strong potential. Investors should review financials, strengths, weaknesses, and sector dynamics before subscribing to the IPO.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
